Diquafosol

Drug Profile

Diquafosol

Alternative Names: DE-089; Diquafosol sodium; Diquafosol tetrasodium; Diquas; Diquas ophthalmic solution 3%; INS 365; INS 365 Ophthalmic; INS 365 Respiratory; KPY 998; Prolacria

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Inspire Pharmaceuticals
  • Developer Inspire Pharmaceuticals; Santen Pharmaceutical
  • Class Expectorants; Eye disorder therapies; Polyphosphates; Small molecules; Uracil nucleotides
  • Mechanism of Action Purinoceptor P2U agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes
  • Discontinued Bronchitis; Chronic obstructive pulmonary disease; Corneal ulcer; Cystic fibrosis

Most Recent Events

  • 10 Jul 2017 Santen Pharmaceutical plans a phase I trial for Dry eyes in Taiwan in July 2017 (NCT03216096)
  • 08 Sep 2016 Santen Pharmaceutical initiates a clinical trial for Dry eyes in Japan (Ophthalmic) (UMIN000024064)
  • 01 Feb 2016 Launched for Dry eyes in Thailand and Vietnam (Topical) before February 2016 (Santen website, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top